You Are Leaving Avistone's Website
You have selected a link that will take you to a site maintained by a third party. Avistone provides this link as a service to website visitors. Avistone is not responsible for the privacy policy of any third party websites. We encourage you to read the privacy policy of every website you visit. Click 'Cancel' to return to Avistone's site or 'Continue' to proceed.
-
2021
12-09
Primavera Invests in Innovative Drug Company Avistone | Primavera Headlines
On December 9, 2021, Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd ("Avistone"), a company focusing on the research of targeted drug for precision treatment announced closure of Series A funding, raising over $200 million from Primavera, Vivo Capital and Bain Capital.
View Details
-
2021
12-09
Avistone Completes over $200 Million Fundraising, with Vivo Capital as the Lead Investor
On December 9, 2021, Beijing Avistone Pharmaceuticals Biotechnology Co., Ltd ("Avistone") announced the closure of Series A funding, raising over $200 million. Vivo Capital was the lead investor, while Bain Capital and Primavera were the co-investors. At the same time, Avistone acquired Beijing Pearl Biotechnology Co., Ltd., another company focusing on clinical trials, thus creating a research platform for various next-generation precision therapy target drugs.
View Details
